Teva and generics in SPC win against MSD

23-03-2017

Teva and generics in SPC win against MSD

Photo: Courtesy of Teva

The English High Court has ruled that a supplementary protection certificate (SPC) owned by Merck Sharp & Dohme (MSD) is invalid because it didn’t comply with European regulations. 


Teva, Mylan, Accord Healthcare, Merck Sharp & Dohme, SPC, supplementary protection certificate, English High Court, HIV, generics

More on this story

Teva sells Paragard contraceptive for $1.1bn
13-09-2017

LSIPR